跳转到主要内容

Long-acting beta2-agonists for bronchiectasis

Long-acting bronchodilators are used in asthma, so may also benefit people with bronchiectasis. However, there is no good evidence for this at present.

研究背景

Symptoms of bronchiectasis include chronic productive cough, wheeze, breathlessness and recurrent infections of the lower respiratory tract. Long-acting bronchodilators are being used more frequently in the management of people with this condition.

研究目的

To determine the effectiveness of long-acting bronchodilators in the management of bronchiectasis that is not due to cystic fibrosis.

检索策略

We searched the Cochrane Airways Group Specialised Register of bronchiectasis trials. The latest searches were carried out in August 2010.

纳入排除标准

Randomised controlled trials, with or without masking.

资料收集与分析

The results of searches were reviewed against pre-specified criteria.

主要结果

We were unable to identify any randomised controlled trials investigating the effectiveness of long-acting bronchodilator therapy in the management of bronchiectasis. An update search in August 2010 did not identify any new studies.

作者结论

Further research is needed to establish if long-acting bronchodilators have a role in the management of people with bronchiectasis.

引用文献
Sheikh A, Nolan D, Greenstone M. Long-acting beta2-agonists for bronchiectasis. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD002155. DOI: 10.1002/14651858.CD002155.

我们的Cookie使用

我们使用必要的cookie来使我们的网站工作。我们还希望设置可选的分析cookie,以帮助我们进行改进。除非您启用它们,否则我们不会设置可选的cookie。使用此工具将在您的设备上设置一个cookie来记住您的偏好。您随时可以随时通过单击每个页面页脚中的“Cookies设置”链接来更改您的Cookie首选项。
有关我们使用cookie的更多详细信息,请参阅我们的Cookies页面

接受全部
配置